<DOC>
	<DOC>NCT00224003</DOC>
	<brief_summary>A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.</brief_summary>
	<brief_title>Study of the Safety and Efficacy of FerrlecitÂ® Maintenance Dosing in Pediatric Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male or female pediatric ESRD, Patients &gt;_ 2 and &lt;_ 16 years of age, whose legally authorized representative provided signed informed consent. Stabilized on chronic hemodialysis therapy with an identified need for maintenance iron therapy. Predetermined TSAT and serum Ferritin (at the screening visit). Receiving a stable EPO dosing regimen. Receipt of any form of iron supplementation during the 2 weeks prior to the first Ferrlecit dosing. Hypersensitivity to Ferrlecit or any of its inactive components. High TSAT level. High Serum Ferritin</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Anemia</keyword>
</DOC>